Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation

NCT00019097 Phase 2 COMPLETED

RATIONALE: Vaccines made from a person's tumor cells may make the body build an immune response and kill their tumor cells. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus vaccine therapy and chemotherapy in treating patients who have multiple myeloma.

Details

Lead sponsor	National Cancer Institute (NCI)
Phase	Phase 2
Status	COMPLETED
Start date	1995-07
Completion	2007-03

Conditions

• Stage II Multiple Myeloma
• Stage III Multiple Myeloma
• Refractory Plasma Cell Neoplasm

Interventions

• autologous tumor cell vaccine
• keyhole limpet hemocyanin
• melphalan
• sargramostim

Countries

United States